Summary
Amgen Inc. reported strong performance in its 2011 fiscal year, with total revenues reaching $15.58 billion, a 4% increase from the previous year, driven by robust sales of its key products like Neulasta®/NEUPOGEN®, Enbrel®, and other growing products such as Prolia® and XGEVA®. The company demonstrated a strong commitment to shareholder returns, initiating its first-ever quarterly cash dividends in 2011 and repurchasing approximately 15% of its outstanding stock for $8.3 billion. Amgen also made strategic acquisitions, including BioVex Group and Laboratório Químico Farmacêutico Bérgamo Ltda, to expand its pipeline and market reach. However, the company recorded a significant $780 million charge related to an agreement in principle to settle allegations concerning its sales and marketing practices. Looking ahead, Amgen faced ongoing challenges including increasing competition from biosimilars, patent expirations on key products, and evolving regulatory and reimbursement landscapes. Despite these headwinds, the company expressed confidence in its future growth opportunities driven by its late-stage pipeline and strategic business development initiatives.
Financial Highlights
55 data points| Revenue | $15.58B |
| Cost of Revenue | $2.71B |
| Gross Profit | $12.87B |
| SG&A Expenses | $4.50B |
| Operating Expenses | $11.27B |
| Operating Income | $4.31B |
| Interest Expense | $610.00M |
| Net Income | $3.68B |
| EPS (Basic) | $4.07 |
| EPS (Diluted) | $4.04 |
| Shares Outstanding (Basic) | 905.00M |
| Shares Outstanding (Diluted) | 912.00M |
Key Highlights
- 1Total revenues increased by 4% to $15.58 billion in 2011, with product sales driven by key products like Neulasta®/NEUPOGEN® and Enbrel®.
- 2Amgen initiated quarterly cash dividends in 2011, paying out $500 million and increasing its quarterly dividend by 29% by year-end.
- 3The company executed a significant share repurchase program, buying back approximately 15% of its outstanding stock for $8.3 billion.
- 4Strategic acquisitions were made, including BioVex Group and Laboratório Químico Farmacêutico Bérgamo Ltda, to strengthen the product pipeline and market presence.
- 5A $780 million charge was recorded in relation to an agreement in principle to settle allegations concerning sales and marketing practices.
- 6Key products like Aranesp® and EPOGEN® experienced sales declines due to regulatory and reimbursement changes, including updated FDA label changes for ESAs.
- 7The company highlighted strong growth for newer products like Prolia® and XGEVA®, with significant revenue contributions in their initial years of broader market availability.